BioStock: CombiGene’s CEO about the path to the first clinical trial
“CombiGene recently strengthened its gene therapy project CG01 in the best possible way when it signed an exclusive, global collaboration and licensing agreement with Spark Therapeutics worth over 320 MUSD. In 2022, the company’s final preparations for the first-in-human study, in collaboration with Spark, are a top priority. BioStock reached out to CombiGene’s CEO Jan Nilsson, to learn about his expectations.”
Read the full interview with Jan Nilsson at biostock.se >>
CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations.
The Company has an exclusive collaboration and licensing agreement for the CG01 project with Spark Therapeutics.
The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 firstname.lastname@example.org.
CombiGene’s lead project CG01 has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 823282